Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse modelCarolyn Waugh Kinkade, Cory Abate‐Shen|Journal of Clinical Investigation|2008Cited by 387